The increase of the aging population presents immense opportunities for bio-pharmaceutical companies to develop candidates to treat global ailments. Dozens of biotech stocks continue to generate significant gains for investors and as the average lifespan continues to increase, the number of drugs being developed to hit the market should follow. The potential for share prices to skyrocket instantaneously on favorable trial news or possible FDA approval is what continues to lure investors into the space.

The NASDAQ Biotechnology Index (NBI) and the iShares NASDAQ Biotech EFT (IBB) are both up about 12 percent over the last trailing year, while the SPDR S&P Biotech ETF (XBI) is showing gains over 20 percent. As the sector continues to heat up, here are 3 bio-pharmaceutical companies that could have potential in their pipelines.

GT Biopharma, Inc. (GTBP)

GT Biopharma is a clinical stage bio-pharmaceutical company focused on developing immune-oncology products based on its proprietary platforms, TriKE, TetraKE and bi-specific Antibody Drug Conjugates (ADC). GTBP’s pipeline consists of seven candidates which include OXS-1550, a protein drug generated to target cancer cells, and OXS-3550, a protein conjugate meant to target CD33+ malignancies.

Notably, the company recently announced it had signed a Material Transfer Agreement (MTA) agreement with a major pharmaceutical company. The agreement details that the pharmaceutical company shall provide GTBP’s lead researcher, Dr. Daniel Vallera, a formulation of its multibillion-dollar widely prescribed oncology drug to be used in the study. Initial pre-clinical work performed by Dr. Vallera suggests a much greater effect when OXS-1550 is given in combination with this established oncology drug.

Evoke Pharma, Inc. (EVOK)

Evoke is a specialty pharmaceutical company which focuses on the development of drugs for the treatment of gastroenterological diseases. It’s lead candidate is Gimoti, a metoclopramide nasal spray, for the treatment of acute and recurrent diabetic gastroparesis in women.

The company announced today via press release that its New Drug Application (NDA) for Gimoti has been accepted for review by the U.S. Food and Drug Administration (FDA). If approved, Gimoti will be the first novel non-oral treatment option for diabetic gastroparesis in forty years.

AVEO Oncology (AVEO)

Aveo is a biopharmaceutical company focused on advancing its portfolio of targeted oncology candidates, all in various stages. The company’s strategy is to maintain North American rights to its pipeline while bringing lead candidate tivozanib to market as a treatment for renal cell carcinoma (RCC). In August 2017, the European Commission (EC) approved tivozanib for the treatment of adult patients with RCC in the European Union, Norway and Iceland.

Aveo had previously partnered with Novartis (NVS) for the development of the AV-380 program and effective August 28, 2018, it intends to regain the rights to AV-380 to continue the program’s development. This week the company reported that the China National Drug Administration has accepted CANbridge Life Sciences’ Investigational New Drug Application for a Phase Ib/III clinical trial of AV-203, which triggers a $2 million milestone payment to Aveo.

An affiliate of MarijuanaStocks.com – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $200,000.00 by GT Biopharma Inc. for a period beginning July 16, 2018 and ending August 16, 2018 to publicly disseminate information about (GTBP). We own zero shares. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.